{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:27:46Z","timestamp":1791779266140,"version":"4.3.4"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81774238"],"award-info":[{"award-number":["81774238"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81373563"],"award-info":[{"award-number":["81373563"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30772689"],"award-info":[{"award-number":["30772689"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Chronic atrophic gastritis (CAG) is a chronic condition characterized by a reduction in gastric mucosal glands and is often regarded as a precursor to gastric cancer. Currently, Western medicine lacks specific treatments for CAG, with management primarily focusing on symptomatic relief and, in cases involving\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      infection, eradication therapy. This study employs a network meta-analysis (NMA) to evaluate the efficacy and safety of the Chinese patent medicine Wei-Fu-Chun (WFC) in the treatment of CAG.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed randomized controlled trials (RCTs) comparing WFC with other interventions for CAG. The outcomes assessed included clinical effectiveness, gastrointestinal symptom scores, gastrointestinal hormone levels, and adverse reactions. The quality of the included studies was assessed with the Cochrane Handbook and GRADEpro software based on the following criteria: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, completeness of outcome data, and selective reporting. Risk ratios were calculated for dichotomous outcomes, and standardized mean differences with 95% confidence intervals were used for continuous variables. Funnel plots were generated to assess publication bias, and treatments were ranked using the surface under the cumulative ranking curve (SUCRA). Data analysis was performed using STATA 15.0 and Review Manager 5.3. The protocol has been registered with PROSPERO under the registration number CRD420251056533.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 38 RCTs involving 3,844 participants were included, and 10 interventions were evaluated: conventional therapy, prokinetics, mucosal-protective agents (MPAs), acid-suppressing drugs (ASDs),\n                      <jats:italic>H<\/jats:italic>\n                      .\n                      <jats:italic>pylori<\/jats:italic>\n                      eradication therapy (HET), WFC, WFC + prokinetics, WFC + MPAs, WFC + ASDs, and WFC + HET. The majority of the included studies were evaluated as having a low risk of bias regarding randomization, attrition, reporting, and other domains, while the risk of bias remained unclear for allocation concealment and blinding. Sensitivity analysis revealed that excluding any single study had a minimal influence on the overall pooled results, and statistical heterogeneity was negligible. The NMA results indicated that WFC combined with MPA ranked the highest in overall clinical efficacy, while WFC combined with prokinetics was the most effective in restoring gastrin (GAS)\/motilin (MTL) levels and alleviating symptom burden. WFC monotherapy also outperformed several Western medications (e.g., MPA, acid inhibitors, and conventional therapy) across multiple outcomes. Combinations of WFC with acid suppressants or prokinetics were associated with fewer adverse events than monotherapies, suggesting a potential reduction in drug-related side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>WFC, particularly in combination with Western medications, enhances clinical efficacy and reduces the incidence of adverse events in patients with CAG. These findings support its potential as a therapeutic option for improving clinical outcomes in CAG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251056533.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1693427","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:17:46Z","timestamp":1763641066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic effect and safety of Wei-Fu-Chun in the treatment of chronic atrophic gastritis: a network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yunbo","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1083-4389.2001.00032.x","article-title":"Two-thirds of atrophic body gastritis patients have evidence of Helicobacter pylori infection","volume":"6","author":"Annibale","year":"2001","journal-title":"Helicobacter"},{"key":"B2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1523-5378.2007.00467.x","article-title":"CagA and VacA are immunoblot markers of past Helicobacter pylori infection in atrophic body gastritis","volume":"12","author":"Annibale","year":"2007","journal-title":"Helicobacter"},{"key":"B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/17474124.2020.1718491","article-title":"A current clinical overview of atrophic gastritis","volume":"14","author":"Annibale","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13020-021-00529-9","article-title":"A correlational study of weifuchun and its clinical effect on intestinal flora in precancerous lesions of gastric cancer","volume":"16","author":"Bian","year":"2021","journal-title":"Chin. Med."},{"key":"B5","first-page":"617","article-title":"Combined therapy with weifuchun and teprenone for chronic atrophic gastritis","volume":"36","author":"Cao","year":"2008","journal-title":"J. Univ. South China Med Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/ajg.2009.728","article-title":"Pathology of gastric intestinal metaplasia: clinical implications","volume":"105","author":"Correa","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0181906","DOI":"10.1371\/journal.pone.0181906","article-title":"The efficacy of jianpi yiqi therapy for chronic atrophic gastritis: a systematic review and meta-analysis","volume":"12","author":"Dai","year":"2017","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"109430","DOI":"10.1016\/j.cellsig.2019.109430","article-title":"Gastric cancer proliferation and invasion is reduced by macrocalyxin C via activation of the miR-212-3p\/Sox6 pathway","volume":"66","author":"Dang","year":"2020","journal-title":"Cell. Signal"},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-230X-14-21","article-title":"Chronic gastritis in China: a national multi-center survey","volume":"14","author":"Du","year":"2014","journal-title":"BMC Gastroenterol."},{"key":"B10","first-page":"2644","article-title":"Effects of Marzulene-S combined with weifuchun on EGF and EGFR in HP-negative patients with chronic atrophic gastritis","volume":"32","author":"Du","year":"2021","journal-title":"Hainan Med. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.5195\/jmla.2018.345","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen","year":"2018","journal-title":"J. Med. Libr. Assoc."},{"key":"B13","first-page":"125","article-title":"Curative efficacy of weifuchun tablets in combination with esomeprazol in treating elderly patients with chronic atrophic gastritis and its effects on serum inflammatory factors","volume":"14","author":"Fan","year":"2017","journal-title":"China Med. Heral"},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.19621\/j.cnki.11-3555\/r.2020.0533","article-title":"Clinical observation of weifuchun tablets combined with rabeprazole sodium enteric-coated capsules in treating chronic atrophic gastritis","volume":"28","author":"Fan","year":"2020","journal-title":"China's Naturop."},{"key":"B14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.16794\/j.cnki.cn33-1207\/r.2011.03.002","article-title":"Comparison of the efficacy of weifuchun combined with teprenone or folic acid in treating chronic atrophic gastritis","volume":"16","author":"Fang","year":"2011","journal-title":"Zhejiang Pract. Med."},{"key":"B15","first-page":"61","article-title":"Efficacy analysis of weifuchun tablets combined with mosapride in treating chronic atrophic gastritis","volume":"38","author":"Gao","year":"2022","journal-title":"Chin. Community Dr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1534735420953215","DOI":"10.1177\/1534735420953215","article-title":"A review of therapeutic effects and the pharmacological molecular mechanisms of Chinese medicine weifuchun in treating precancerous gastric conditions","volume":"19","author":"Gu","year":"2020","journal-title":"Cancer Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.cgh.2024.09.003","article-title":"Global progression rates of precursor lesions for gastric cancer: a systematic review and meta-analysis","volume":"23","author":"Hahn","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.14009\/j.issn.1672-2124.2017.05.028","article-title":"Efficacy of weifuchun tablets combined with polaprezine granules in treatment of atrophic gastritis and effects on inflammatory cytokine level","volume":"17","author":"He","year":"2017","journal-title":"Eval. Analysis Drug-Use Hosp. China"},{"key":"B20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.19381\/j.issn.1001-7585.2021.06.023","article-title":"Effects of weifuchun combined with quadruple therapy on gastrointestinal hormones and immune function in patients with chronic atrophic gastritis","volume":"34","author":"Hu","year":"2021","journal-title":"J Med Theor and Prac"},{"key":"B21","doi-asserted-by":"publisher","first-page":"10553","DOI":"10.3748\/wjg.v21.i37.10553","article-title":"Endoscopic surveillance of gastric cancers after Helicobacter pylori eradication","volume":"21","author":"Kobayashi","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B23","first-page":"25","article-title":"Clinical efficacy observation of weifuchun combined with bifidobacterium in treating patients with chronic atrophic gastritis","volume":"2","author":"Li","year":"2018","journal-title":"J. Bingtuan Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.13288\/j.11-2166\/r.2023.02.019","article-title":"Expert consensus on the clinical application of weifuchun in treating precancerous lesions of chronic atrophic gastritis","volume":"64","author":"Li","year":"2023","journal-title":"J. Traditional Chin. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.13638\/j.issn.1671-4040.2020.11.034","article-title":"Effects of weifuchun tablets combined with mosapride on chronic atrophic gastritis","volume":"20","author":"Li","year":"2020","journal-title":"Pract. J. Integr. Tradit. Chin. West Med."},{"key":"B25","first-page":"140","article-title":"Observation on the efficacy of quadruple therapy combined with weifuchun in the treatment of chronic atrophic gastritis","volume":"33","author":"Liang","year":"2021","journal-title":"Strait Pharm. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.19960\/j.cnki.issn1005-0698.2011.06.006","article-title":"Efficacy observation of weifuchun in treating precancerous lesions of chronic atrophic gastritis","volume":"20","author":"Lin","year":"2011","journal-title":"Chin. J. Pharmacoepidemiol"},{"key":"B27","first-page":"48","article-title":"Efficacy observation of triple therapy for Helicobacter pylori eradication combined with weifuchun in treating chronic atrophic gastritis","volume":"30","author":"Lin","year":"2010","journal-title":"J. Gannan Med. Univ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.14009\/j.issn.1672-2124.2018.09.012","article-title":"Observation on efficacy of Weifuchun tablets combined with mosapride tablets in treatment of chronic atrophic gastritis","volume":"18","author":"Liu","year":"2018","journal-title":"Eval. Analysis Drug-Use Hosp. China"},{"key":"B30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.16305\/j.1007-1334.2017.02.013","article-title":"Clinical observation and mechanism of Weifuchun in treating gastric intestinal metaplasia. SH","volume":"51","author":"Liu","year":"2017","journal-title":"J. TCM"},{"key":"B28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.16096\/J.cnki.nmgyxzz.2022.54.03.028","article-title":"Clinical efficacy of combined medication in treating Helicobacter pylori-associated chronic atrophic gastritis","volume":"54","author":"Liu","year":"2022","journal-title":"Inn. Mong. Med. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.19381\/j.issn.1001-7585.2019.07.028","article-title":"Observation on the efficacy of Weifuchun tablets in treating chronic atrophic gastritis","volume":"32","author":"Long","year":"2019","journal-title":"J Med Theor and Prac"},{"key":"B32","first-page":"2182","article-title":"Clinical efficacy of weifuchun pill on Helicobacter pylori positive chronic atrophic gastritis and effects on pH and pepsinogen in gastric juice","volume":"13","author":"Lu","year":"2018","journal-title":"World Chin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.14309\/ajg.0000000000003350","article-title":"ACG clinical guideline: diagnosis and management of gastric premalignant conditions","volume":"120","author":"Morgan","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"B34","first-page":"265","article-title":"Observation on pathological improvement of chronic atrophic gastritis treated with weifuchun and rebamipide","volume":"32","author":"Nie","year":"2011","journal-title":"J. Jilin Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2169\/internalmedicine.2292-18","article-title":"Prevalence of autoimmune Gastritis in individuals undergoing medical checkups in Japan","volume":"58","author":"Notsu","year":"2019","journal-title":"Intern Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1472-6882-10-45","article-title":"Protective effects of a gastrointestinal agent containing Korean red ginseng on gastric ulcer models in mice","volume":"10","author":"Oyagi","year":"2010","journal-title":"BMC Complement. Altern. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1097\/PAS.0b013e3181f623af","article-title":"Gastric lesions in patients with autoimmune metaplastic atrophic gastritis (AMAG) in a tertiary care setting","volume":"34","author":"Park","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1097\/PAS.0000000000000481","article-title":"Autoimmune metaplastic atrophic gastritis: recognizing precursor lesions for appropriate patient evaluation","volume":"39","author":"Pittman","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1046\/j.1365-2036.2002.01301.x","article-title":"Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading","volume":"16","author":"Rugge","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/2046-4053-3-37","article-title":"Evaluation of the cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation","volume":"3","author":"Savovic","year":"2014","journal-title":"Syst. Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1053\/j.gastro.2021.06.078","article-title":"AGA clinical practice update on the diagnosis and management of atrophic gastritis: expert review","volume":"161","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1055-9965.EPI-16-1024","article-title":"High salt intake is associated with atrophic gastritis with intestinal metaplasia","volume":"26","author":"Song","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14033\/j.cnki.cfmr.2019.17.003","article-title":"Clinical efficacy of weifuchun tablets combined with lansoprazole in treating chronic atrophic gastritis and its impact on serum IL-1\u03b2 levels","volume":"17","author":"Song","year":"2019","journal-title":"Chin. Foreign Med. Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"B50","doi-asserted-by":"publisher","first-page":"115930","DOI":"10.1016\/j.jep.2022.115930","article-title":"Exploring the effect of weifuchun capsule on the toll-like receptor pathway mediated HES6 and immune regulation against chronic atrophic gastritis","volume":"303","author":"Wang","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"B48","first-page":"118","article-title":"Therapeutic effect of the combination of weifuchun tablets and lansoprazole in the treatment of chronic atrophic gastritis and its impact on the serum inflammatory index levels of patients","volume":"5","author":"Wang","year":"2024","journal-title":"RARM"},{"key":"B49","first-page":"1983","article-title":"Clinical observation of weifuchun capsules in treating atrophic gastritis with intestinal metaplasia","volume":"37","author":"Wang","year":"2022","journal-title":"CJGMCM"},{"key":"B52","doi-asserted-by":"publisher","first-page":"558471","DOI":"10.3389\/fphar.2020.558471","article-title":"A combined phytochemistry and network pharmacology approach to reveal the effective substances and mechanisms of wei-fu-chun tablet in the treatment of precancerous lesions of gastric cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.19296\/j.cnki.1008-2409.2021-03-006","article-title":"Observation on the efficacy of weifuchun tablets combined with rabeprazole quadruple therapy in patients with chronic atrophic gastritis and Hp infection","volume":"34","author":"Wang","year":"2021","journal-title":"Acta Med. Sin."},{"key":"B53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.13457\/j.cnki.jncm.2024.06.016","article-title":"Clinical study on weifuchun combined with bismuth quadruple therapy for atrophic gastritis complicated with Hp infection","volume":"56","author":"Wang","year":"2024","journal-title":"New Chin. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0284411","DOI":"10.1371\/journal.pone.0284411","article-title":"Efficacy and safety of weifuchun tablet for chronic atrophic gastritis: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"key":"B51","doi-asserted-by":"publisher","first-page":"372","DOI":"10.4103\/pm.pm_179_16","article-title":"Mechanism of fructus aurantii flavonoids promoting gastrointestinal motility: from organic and inorganic endogenous substances combination point of view","volume":"13","author":"Wang","year":"2017","journal-title":"Mag"},{"key":"B46","first-page":"178","article-title":"Effects of weifuchun tablets combined with esomeprazole on IL-6, IL-8, and TNF-\u03b1 levels in patients with chronic atrophic gastritis","volume":"6","author":"Wang","year":"2020","journal-title":"World J. Complex Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.15887\/j.cnki.13-1389\/r.2020.13.028","article-title":"Clinical efficacy of weifuchun tablets combined with lansoprazole in treating chronic atrophic gastritis and its impact on serum soluble interleukin-2 receptor","volume":"13","author":"Wu","year":"2020","journal-title":"Chin J Clin. Ration. Drug Use"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.19381\/j.issn.1001-7585.2018.18.019","article-title":"Clinical efficacy and safety of weifuchun combined with esomeprazole in treating chronic atrophic gastritis","volume":"31","author":"Xiao","year":"2018","journal-title":"J. Med. Theor. Prac"},{"key":"B57","doi-asserted-by":"publisher","first-page":"117020","DOI":"10.1016\/j.jep.2023.117020","article-title":"Wei-fu-chun tablet halted gastric intestinal metaplasia and dysplasia associated with inflammation by regulating the NF-\u03baB pathway","volume":"318","author":"Xie","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.16368\/j.issn.1674-8999.2018.08.364","article-title":"Clinical study on weifuchun in treating for chronic atrophic gastritis","volume":"33","author":"Xu","year":"2018","journal-title":"Acta Chin. Med."},{"key":"B59","first-page":"2441","article-title":"Clinical study of cinitapride combined with weifuchun tablets in treating chronic atrophic gastritis","volume":"35","author":"Yao","year":"2020","journal-title":"Drugs and Clin."},{"key":"B60","first-page":"80","article-title":"Clinical observation of the efficacy of dahuang zhechong tablet combined with weifuchun capsule in the treatment of chronic atrophic gastritis with intestinal metaplasia","volume":"62","author":"Ye","year":"2024","journal-title":"China Mod. Dr."},{"key":"B61","first-page":"49","article-title":"Study on the relationship between the course and the curative effect of the weifuchun capsule on the chronic atrophic gastritis","volume":"36","author":"Yuan","year":"2016","journal-title":"Clin. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"696","DOI":"10.13241\/j.cnki.pmb.2012.04.032","article-title":"Study on weifuchun and rebamipide combination therapy for chronic atrophic gastritis","volume":"12","author":"Zhang","year":"2012","journal-title":"Prog. Mod. Biomed."},{"key":"B64","first-page":"1384","article-title":"Clinical study of weifuchun tablets combined with compound proglumide and cimetidine in treating chronic atrophic gastritis","volume":"34","author":"Zhang","year":"2019","journal-title":"Drugs and Clin."},{"key":"B65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.14163\/j.cnki.11-5547\/r.2025.07.019","article-title":"Analysis of the curative effect of rebamipide combined with weifuchun in the treatment of patients with chronic atrophic gastritis","volume":"20","author":"Zhang","year":"2025","journal-title":"China Prac. Med."},{"key":"B62","first-page":"81","article-title":"Observation on the efficacy of weifuchun tablets combined with lansoprazole in treating patients with chronic atrophic gastritis","volume":"6","author":"Zhang","year":"2022","journal-title":"Mod. Med. Health Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.13457\/j.cnki.jncm.2017.02.013","article-title":"Observation of folic acid tablets combined with weifuchun tablets in treating precancerous lesions of chronic atrophic gastritis","volume":"49","author":"Zhou","year":"2017","journal-title":"J. New Chin. Med."},{"key":"B67","first-page":"57","article-title":"Clinical efficacy of bifidobacteria combined with weifuchun in treating chronic atrophic gastritis","volume":"3","author":"Zhu","year":"2019","journal-title":"Mod. Med. Health Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1693427\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:18:03Z","timestamp":1763641083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1693427\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":67,"alternative-id":["10.3389\/fphar.2025.1693427"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1693427","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1693427"}}